



Hematopoietic Cellular Transplant (HCT) Infusion

Registry Use Only

Sequence Number: _____

Date Received: _____

OMB No: 0915-0310

Expiration Date: 10/31/2022

Public Burden Statement: An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. The OMB control number for this project is 0915-0310. Public reporting burden for this collection of information, in combination with the IDM Form 2004 and HLA Typing Form 2005, is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to HRSA Reports Clearance Officer, 5600 Fishers Lane, Room 14N39, Rockville, Maryland, 20857.

CIBMTR Center Number: _____

CIBMTR Research ID: _____

Event Date: __ __ / __ __ / __ __
 YYY MM DD

HCT type (check only one) Autologous Allogeneic, unrelated Allogeneic, related

Product type (check only one) Bone marrow

PBSC

Single cord blood unit

Other product. Specify: _____

NMDP Product Yes No

Product Identifiers:

NMDP cord blood unit ID: _____

Registry donor ID: _____

Non-NMDP cord blood unit ID: _____

Global Registration for Identifier for Donors (GRID): _____

ISBT DIN: _____

Registry or UCB Bank ID: _____

Donor DOB: __ __ __ __ / __ __ / __ __
 YYYY MM DD

Donor Age: __ __ Months (use only if less than 1 year old) Years

Donor Sex Male Female

If more than one type of HCT product is infused, each product type must be analyzed and reported separately.

A series of collections should be considered a single product when they are all from the same donor and use the same collection method and technique (and mobilization, if applicable), even if the collections are performed on different days.

Pre-Collection Therapy

1. Did the donor receive growth and mobilizing factors, prior to any stem cell harvest, to enhance the product collection for this HCT? **Allogeneic donors only**

- Yes →
- No

2. Specify growth and mobilizing factor(s) (Check all that apply)

- G-CSF (filgrastim, Neupogen)
- Pegylated G-CSF (pegfilgrastim, Neulasta)
- Plerixafor (Mozobil)
- Other growth or mobilizing factor(s) →

3. Specify other growth or mobilizing factor(s):

Product Collection

4. Date of first collection for this mobilization: __ __ / __ __ / __ __
 YYYY MM DD

5. Were anticoagulants or other agents added to the product between collection and infusion?

- Yes →
- No

6. Specify anticoagulant(s) or other agents (check all that apply)

- Acid citrate dextrose (ACD, ACD-A)
- Citrate phosphate dextrose (CPD, CPD-A)
- Ethylenediaminetetraacetic acid (EDTA)
- Heparin
- Other agent →

7. Specify other agent:

Product Transport and Receipt

8. Was this product collected off-site and shipped to your facility?

- Yes →
- No

9. Date of receipt of product at your facility: __ __ / __ __ / __ __
 YYYY MM DD

10. Time of receipt of product (24-hour clock):

__ : __ standard time daylight savings time
 Hour Minute

11. Specify the shipping environment of the product(s)

- Room temperature
- Cooled (refrigerator temperature, not frozen)
- Frozen (cryopreserved)
- Other shipping environment →

12. Specify other shipping environment:

13. Was there any indication that the environment within the shipper was outside the expected temperature range for this product at any time during shipment?

- Yes
- No

14. Were the secondary containers (e.g., insulated shipping containers and unit cassette) intact when they arrived at your center?

- Yes
- No

15. Was the cord blood unit stored at your center prior to thawing? **(Cord blood units only)**

- Yes →
- No

16. Specify the storage method used for the cord blood unit
 Electric freezer Liquid nitrogen Vapor phase

17. Temperature during storage
 < -150° C
 ≥ -150° C to < -135° C
 ≥ -135° C to < -80° C
 ≥ -80° C

18. Date storage started: ____/____/____
YYYY MM DD

Report the total number of cells (not cells per kilogram) prior to cryopreservation: (Information provided for the unit by the cord blood bank).

19. Total nucleated cells: _____ • _____ x 10 _____ (Includes nucleated red and nucleated white cells) **(Cord blood units only)**

20. CD34+ cells **(cord blood units only)**

- Done →
- Not done

21. Total number of CD34+ cells:
 _____ • _____ x 10 _____

Product Processing / Manipulation

22. Was the product thawed from a cryopreserved state prior to infusion?

- Yes →
 No

23. Was the entire product thawed?

- Yes
 No →

24. Specify the percent of the product that was thawed? (**Cord blood units only**)

- 80%
 20%
 Other percent →

25. Specify other percent: ___ %

26. Date thawing process initiated: ___ / ___ / ___
YYYY MM DD

27. Time at initiation of thaw (24-hour clock): ___ : ___ standard time daylight savings time
Hour Minute

28. Time of thaw completion (24-hour clock): ___ : ___ standard time daylight savings time
Hour Minute

29. What method was used to thaw the product?

- Waterbath
 Electric warmer
 Other method →

30. Specify other method: _____

31. Did any incidents, or product complaints occur while preparing or thawing the product? Yes No

32. Was the product **processed** prior to infusion?

- Yes →
 No

33. Specify processing (check all that apply)

- Buffy coat enriched (buffy coat preparation)
 Diluted
 Plasma reduced
 RBC reduced
 Washed

34. Was the product **manipulated** prior to infusion?

- Yes →
 No

35. Specify manipulations performed (check all that apply)

- Ex-vivo expansion - **Go to question 41**
 Genetic manipulation (gene transfer / transduction) - **Go to question 41**
 CD34 enriched (CD34+ selection) - **Go to question 41**
 Ex-vivo T-cell depletion - **Go to question 36**
 Other manipulation - **Go to question 40**

50. Nucleated white blood cells

- Done →
- Not done

51. Total number of nucleated white blood cells: _____ • _____ x 10 _____

52. Mononuclear cells

- Done →
- Not done

53. Total number of mononuclear cells: _____ • _____ x 10 _____

54. Nucleated red blood cells

- Done →
- Not done

55. Total number of nucleated red blood cells: _____ • _____ x 10 _____

56. CD34+ cells

- Done →
- Not done

57. Total number of CD34+ cells: _____ • _____ x 10 _____

58. Viability of CD34+ cells

- Done →
- Not done
- Unknown

59. Viability of CD34+ cells: _____ %

60. Method of testing CD34+ cell viability

- Flow cytometry based
- Trypan blue
- Other method →

61. Specify other method: _____

62. CD3+ cells

- Done →
- Not done

63. Total number of CD3+ cells: _____ • _____ x 10 _____

64. Viability of CD3+ cells

- Done →
- Not done
- Unknown

65. Viability of CD3+ cells cells: _____ %

66. Method of testing CD3+ cells cell viability

- Flow cytometry based
- Trypan blue
- Other method →

67. Specify other method: _____

68. CD3+CD4+ cells

- Done →
 Not done

69. Total number of CD3+CD4+ cells: _____ • _____ x 10 _____

70. Viability of CD3+CD4+ cells

Done →
 Not done
 Unknown

71. Viability of CD3+CD4+ cells: _____ %

72. Method of testing CD3+CD4+ cell viability

Flow cytometry based
 Trypan blue
 Other method →

73. Specify other method: _____

74. CD3+CD8+ cells

- Done →
 Not done

75. Total number of CD3+CD8+ cells: _____ • _____ x 10 _____

76. Viability of CD3+CD8+ cells

Done →
 Not done
 Unknown

77. Viability of CD3+CD8+ cells: _____ %

78. Method of testing CD3+CD8+ cell viability

Flow cytometry based
 Trypan blue
 Other method →

79. Specify other method: _____

80. Were the colony-forming units (CFU) assessed after thawing? **(cord blood units only)**

- Yes →
 No

81. Was there growth? Yes No

82. Total CFU-GM

Done →
 Not done

83. Total CFU-GM: _____ • _____ x 10 _____

84. Total CFU-GEMM

Done →
 Not done

85. Total CFU-GEMM: _____ • _____ x 10 _____

86. Total BFU-E

Done →
 Not done

87. Total BFU-E: _____ • _____ x 10 _____

88. Were any positive cultures (for bacterial or fungal infections) obtained from the product at the transplant center? (complete for all cell products)

- Yes →
- No
- Pending
- Unknown

Specify organism code(s):

89. _____ 90. _____ 91. _____ 92. _____

93. Specify organism: _____

‡ The codes for "other organism, specify" (codes 198, 209, 219 and 259) should rarely be needed; check with your microbiology lab or HCT physician before using them.

Codes for Commonly Reported Organisms

Bacterial Infections

- 121 Acinetobacter (all species)
- 125 Bordetella pertussis (whooping cough)
- 128 Campylobacter (all species)
- 129 Capnocytophaga (all species)
- 171 Chlamydia (pneumoniae)
- 130 Citrobacter (freundii, other species)
- 131 Clostridium (all species except difficile)
- 132 Clostridium difficile
- 173 Corynebacterium jeikeium
- 134 Enterobacter (all species)
- 135 Enterococcus (all species)
- 177 Enterococcus, vancomycin resistant (VRE)
- 136 Escherichia (also E. coli)
- 139 Fusobacterium (all species)
- 187 Haemophilus influenzae
- 188 Haemophilus non-influenzae
- 146 Klebsiella (all species)
- 147 Lactobacillus (bulgaricus, acidophilus, other species)
- 189 Legionella pneumophila
- 190 Legionella non-pneumophila
- 103 Leptospira (all species)
- 148 Leptotrichia buccalis
- 149 Leuconostoc (all species)
- 104 Listeria monocytogenes
- 151 Micrococcus, NOS
- 118 Mycobacterium abscessus
- 112 Mycobacterium avium - intracellulare (MAC, MAI)
- 108 Mycobacterium chelonae
- 109 Mycobacterium fortuitum
- 114 Mycobacterium haemophilum
- 115 Mycobacterium kansasii
- 116 Mycobacterium marinum
- 117 Mycobacterium mucogenicum
- 110 Mycobacterium tuberculosis (tuberculosis, Koch bacillus)

- 105 Mycoplasma (all species)
- 183 Neisseria gonorrhoeae
- 184 Neisseria meningitidis
- 106 Nocardia (all species)
- 153 Pasteurella multocida
- 155 Proteus (all species)
- 157 Pseudomonas or Burkholderia cepacia
- 185 Pseudomonas aeruginosa
- 186 Pseudomonas non-aeruginosa
- 159 Rhodococcus (all species)
- 107 Rickettsia (all species)
- 160 Salmonella (all species)
- 161 Serratia marcescens
- 162 Shigella (all species)
- 180 Staphylococcus (Methacillin Resistant)
- 179 Staphylococcus (Methacillin Sensitive)
- 158 Stenotrophomonas maltophilia
- 166 Stomatococcus mucilaginosus
- 181 Streptococcus, alpha-hemolytic
- 182 Streptococcus, Group B
- 178 Streptococcus pneumoniae
- 168 Treponema (syphilis)
- 169 Vibrio (all species)

Fungal Infections

- 210 Aspergillus, NOS
- 211 Aspergillus flavus
- 212 Aspergillus fumigatus
- 213 Aspergillus niger
- 215 Aspergillus terreus
- 214 Aspergillus ustus
- 270 Blastomyces (dermatitidis)
- 201 Candida albicans
- 208 Candida non-albicans
- 271 Coccidioides (all species)
- 222 Cryptococcus gattii
- 221 Cryptococcus neoformans
- 230 Fusarium (all species)
- 261 Histoplasma (capsulatum)
- 241 Mucorales (all species)
- 260 Pneumocystis (PCP / PJP)
- 242 Rhizopus (all species)
- 272 Scedosporium (all species)

240 Zygomycetes, NOS
 503 Suspected fungal infection
 777 Other organism

Copy questions 41-93 to report multiple instances of Product Analysis

Product Infusion

94. Date of this product infusion: __ __ / __ __ / __ __
YYYY MM DD

95. Was the entire volume of received product infused?

Yes

No →

96. Specify what happened to the reserved portion:

Discarded

Cryopreserved for future use

Other fate →

97. Specify other fate: _____

98. Time product infusion initiated (24-hour clock): __ __ : __ __ standard time daylight savings time
Hour Minute

99. Date infusion stopped: __ __ / __ __ / __ __
YYYY MM DD

100. Time product infusion completed (24-hour clock): __ __ : __ __ standard time daylight savings time
Hour Minute

101. Specify the route of product infusion

Intravenous

Intramedullary (Intraosseous)

Other route of infusion →

102. Specify other route of infusion: _____

The following questions are applicable to cord blood units only. Non-NMDP allogeneic products continue with question 144. Autologous and NMDP products continue with the signature lines.

103. Were there any adverse events or incidents associated with the stem cell infusion?

Yes →

No

Specify the following adverse event(s):

104. Brachycardia

Yes →

No

105. In the Medical Director's judgment, was the adverse event a direct result of the infusion?

Yes No

106. Chest tightness / pain

Yes →

No

107. In the Medical Director's judgment, was the adverse event a direct result of the infusion?

Yes No

108. Chills at time of infusion

Yes →

No

109. In the Medical Director's judgment, was the adverse event a direct result of the infusion?

Yes No

110. Fever $\leq 103^\circ$ F within 24 hours of infusion

Yes →

No

111. In the Medical Director's judgment, was the adverse event a direct result of the infusion?

Yes No

112. Fever $> 103^\circ$ F within 24 hours of infusion

Yes →

No

113. In the Medical Director's judgment, was the adverse event a direct result of the infusion?

Yes No

114. Gross hemoglobinuria

Yes →

No

115. In the Medical Director's judgment, was the adverse event a direct result of the infusion?

Yes No

116. Headache

- Yes →
- No

117. In the Medical Director's judgment, was the adverse event a direct result of the infusion?

- Yes
- No

118. Hives

- Yes →
- No

119. In the Medical Director's judgment, was the adverse event a direct result of the infusion?

- Yes
- No

120. Hypertension

- Yes →
- No

121. In the Medical Director's judgment, was the adverse event a direct result of the infusion?

- Yes
- No

122. Hypotension

- Yes →
- No

123. In the Medical Director's judgment, was the adverse event a direct result of the infusion?

- Yes
- No

124. Hypoxia requiring oxygen (O₂) support

- Yes →
- No

125. In the Medical Director's judgment, was the adverse event a direct result of the infusion?

- Yes
- No

126. Nausea

- Yes →
- No

127. In the Medical Director's judgment, was the adverse event a direct result of the infusion?

- Yes
- No

128. Rigors, mild

- Yes →
- No

129. In the Medical Director's judgment, was the adverse event a direct result of the infusion?

- Yes
- No

130. Rigors, severe

- Yes →
- No

131. In the Medical Director's judgment, was the adverse event a direct result of the infusion?

- Yes
- No

132. Shortness of breath (SOB)

- Yes →
- No

133. In the Medical Director's judgment, was the adverse event a direct result of the infusion?

- Yes
- No

134. Tachycardia

- Yes →
- No

135. In the Medical Director's judgment, was the adverse event a direct result of the infusion?

- Yes
- No

136. Vomiting

- Yes →
- No

137. In the Medical Director's judgment, was the adverse event a direct result of the infusion?

- Yes
- No

138. Other expected AE

- Yes →
- No

139. Specify other expected AE: _____

140. In the Medical Director's judgment, was the adverse event a direct result of the infusion?

- Yes
- No

141. Other unexpected AE

- Yes →
- No

142. Specify other unexpected AE: _____

143. In the Medical Director's judgment, was the adverse event a direct result of the infusion?

- Yes
- No

Donor / Infant Demographic Information

This Donor Demographic Information section (questions 144-170) is to be completed for all non-NMDP allogeneic donors. If the stem cell product was from an NMDP donor or an autologous donor, continue with the signature lines.

144. Was the donor ever pregnant?

- Yes →
- No
- Unknown
- Not applicable (male donor or cord blood unit)

145. Number of pregnancies

- Known →
- Unknown

146. Specify number of pregnancies: _____

147. Ethnicity (donor) Hispanic or Latino Not Hispanic or Latino Not applicable (not a resident of the USA) Unknown

148. Race (donor) (check all that apply)

- White - **Go to Question 149**
- Black or African American - **Go to Question 149**
- Asian - **Go to Question 149**
- American Indian or Alaska Native - **Go to Question 149**
- Native Hawaiian or Other Pacific Islander - **Go to Question 149**
- Not reported - **Go to Question 151**
- Unknown - **Go to Question 151**

149. Race detail (donor) (check all that apply)

- Eastern European
- Mediterranean
- Middle Eastern
- North Coast of Africa
- North American
- Northern European
- Western European
- White Caribbean
- White South or Central American
- Other White
- African (both parents born in Africa)
- African American
- Black Caribbean
- Black South or Central American
- Other Black
- Alaskan Native or Aleut
- North American Indian
- American Indian, South or Central America
- Caribbean Indian
- South Asian
- Filipino (Pilipino)
- Japanese
- Korean
- Chinese
- Vietnamese

- Other Southeast Asian
- Guamanian
- Hawaiian
- Samoan
- Other Pacific Islander
- Unknown

150. Was the donor a carrier for potentially transferable genetic diseases?

- Yes →
- No

151. Specify potentially transplantable genetic disease (check all that apply)

- Sickle cell anemia
- Thalassemia
- Other hemoglobinopathy
- Other disease →

152. Specify other disease: _____

153. Was the donor / product tested for other transferable genetic or clonal abnormalities?

- Yes - **Go to question 154**
- No - **If this is a related donor, go to question 159; all other donor types go to signature line**
- Unknown - **If this is a related donor, go to question 159; all other donor types go to signature line**

154. Clonal hematopoiesis of indeterminate potential (CHIP)

- Yes →
- No

155. What was the method of testing used? _____

156. Monoclonal B-cell lymphocytosis

- Yes
- No

157. Other transferable genetic or clonal abnormality

- Yes →
- No

158. Specify other transferable genetic or clonal abnormality:

The following questions (160–167) apply only to allogeneic related donors. If the stem cell product was from an autologous donor, Non-NMDP unrelated donor, NMDP donor, or was a cord blood unit, then continue with the signature lines.

159. Did this donor have a central line placed?

- Yes
- No
- Unknown

160. Was the donor hospitalized (inpatient) during or after the collection?

- Yes
- No

161. Did the donor experience any life-threatening complications during or after the collection?

- Yes →
- No

162. Specify: _____

